Search results for: Determining Value
Filter search results
New OHE Report: Time Trends in NICE HTA Decisions
25 January 2012
…innovative care and ensure more rapid access to medicines identified as being of value to the NHS. Since NICE’s debut in April 1999, several analyses have examined the uptake of…
Enhancing the Benefits from Biomedical and Health Research Spillovers
1 October 2010
…the ultimate value of this transfer of ideas, knowledge or know-how still are… Research spillovers may exist when research by one organisation creates increased output for other organisations that operate…
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
…impressive… and an important contribution to the debate surrounding the optimal value of the threshold to be applied by NICE” but argue that more work is needed to validate or…
Do Respondents Completing Abstract, Hypothetical Priority-Setting Exercises Agree with the Policy Implications of Their Choices?
3 March 2015
A new OHE Consulting Report examines whether respondents completing abstract, hypothetical priority-setting exercises in stated preference studies agree with the policy implications of their choices. Stated preference studies are increasingly…
What Determines the Shape of an EQ-5D Index Distribution?
1 August 2014
…that may obscure useful, and important, information about health states. Distributions of EQ-5D index values in patient and general populations typically divide into two distinct groups, the authors note. This…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
Histology independent therapies are changing the picture of cancer treatment and in so doing don’t ‘fit the frame’ of value assessment. What are the key challenges on the pathway from…
Comparing the EQ-5D-3L and EQ-5D-5L in a Cohort of Cancer Patients: A Research Collaboration between OHE, Curtin University and King’s College London
15 August 2017
…large cohort of cancer patients. The existence of important dissimilarities between EQ-5D-3L and the newer EQ-5D-5L, in terms of both the health profiles and preference-based values, is a key topic…
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
1 December 2018
…current approaches to MIP in Europe, the perceived challenges, and how they could be tackled in the future. Multi-indication pricing (MIP) is based on the idea of recognising the value…
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…prices. The long run price of prescription drugs depends on the nature and consequences of generic competition which reduces drug prices significantly after patent expiration. To estimate the value that…